Show simple item record

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.

dc.contributor.authorRizzo, A
dc.contributor.authorRacca, M
dc.contributor.authorDall'Armellina, S
dc.contributor.authorRescigno, P
dc.contributor.authorBanna, GL
dc.contributor.authorAlbano, D
dc.contributor.authorDondi, F
dc.contributor.authorBertagna, F
dc.contributor.authorAnnunziata, S
dc.contributor.authorTreglia, G
dc.coverage.spatialSwitzerland
dc.date.accessioned2023-04-03T11:07:16Z
dc.date.available2023-04-03T11:07:16Z
dc.date.issued2023-01-05
dc.identifierARTN 355
dc.identifiercancers15020355
dc.identifier.citationCancers, 2023, 15 (2), pp. 355 -en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5734
dc.identifier.eissn2072-6694
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers15020355
dc.description.abstractBACKGROUND: Recent articles proposed the employment of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in clear cell renal cell carcinoma (ccRCC). METHODS: The authors performed a comprehensive literature search of studies on the performance of PET/CT with PSMA-targeting radiopharmaceuticals in ccRCC. Original articles concerning this imaging examination were included in newly diagnosed ccRCC patients and ccRCC patients with disease recurrence. RESULTS: A total of sixteen papers concerning the diagnostic performance of PSMA-targeted PET/CT in ccRCC (331 patients) were included in this systematic review. The included articles demonstrated an excellent detection rate of PSMA-targeting PET/CT in ccRCC. CONCLUSIONS: PSMA-targeted PET/CT seems promising in detecting ccRCC lesions as well as in discriminating the presence of aggressive phenotypes. Prospective multicentric studies are warranted to strengthen the role of PSMA-targeting PET/CT in ccRCC.
dc.formatElectronic
dc.format.extent355 -
dc.languageeng
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofCancers
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectPET
dc.subjectPSMA
dc.subjectclear cell renal cell carcinoma
dc.subjectimaging
dc.subjectkidney
dc.subjectnuclear medicine
dc.subjectoncology
dc.titleThe Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-01-03
dc.date.updated2023-04-03T11:04:35Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cancers15020355en_US
rioxxterms.licenseref.startdate2023-01-05
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36672305
pubs.issue2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.3390/cancers15020355
pubs.volume15
icr.researchteamPrCa Targeted Therapyen_US
dc.contributor.icrauthorRescigno, Pasquale
icr.provenanceDeposited by Mr Arek Surman on 2023-04-03. Deposit type is initial. No. of files: 1. Files: The Emerging Role of PETCT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer An Updated Systematic Review.pdf


Files in this item

Thumbnail
Name:
The Emerging Role of PETCT with ...
Size:
933.3Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/